Stay updated on Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision: v3.4.3 added; revision changed from v3.4.2. No substantive changes to the study details are evident.
    Difference
    0.1%
    Check dated 2026-03-11T12:25:12.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; removed the lapse-in-government-funding notice and the older Revision: v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-11T02:38:14.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The page now displays an administrative notice about funding status and the NIH Clinical Center's operations, along with a new revision tag (Revision: v3.4.1). These changes do not modify trial data, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-03T23:49:49.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The page now displays a Show glossary option and new metadata fields (Last Update Submitted that Met QC Criteria and Last Update Posted) along with No FEAR Act Data and Revision: v3.4.0, replacing the previous labels (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4).
    Difference
    0.3%
    Check dated 2026-01-27T21:32:00.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    New data points were added to the study record, including several key dates (2026-01-02, 2023-08-04, 2027-09-01, 2025-12-30) and a Last Update Posted (Estimated) label. Older sponsor details and past update entries (e.g., Nancy Chan, MD, Big Ten Cancer Research Consortium) were removed.
    Difference
    0.8%
    Check dated 2026-01-06T02:04:22.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    - Added a new Locations section listing Michigan, Nebraska, New Jersey, New York, and Wisconsin. Removed the separate Michigan, Nebraska, New Jersey, New York, and Wisconsin location blocks.
    Difference
    0.7%
    Check dated 2025-12-22T20:39:48.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.